3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
3
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Breast Neoplasms
21
Prostatic Neoplasms
17
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Lung Neoplasms
10
Neoplasms
7
Neoplasm Metastasis
6
Carcinoma, Transitional Cell
5
Triple Negative Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Small Cell Lung Carcinoma
3
Salivary Gland Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Carcinoma
3
Recurrence
2
Osteosarcoma
2
Non-Muscle Invasive Bladder Neoplasms
2
Lymphoid Interstitial Pneumonia
2
Laryngeal Neoplasms
2
HER2-positive Breast Cancer
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Interventions
cemiplimab
2
zimberelimab
1
quemliclustat
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Advanced Non-Small Cell Lung Cancer
×
Docetaxel
×
Clear all
NCT05676931
2026-06-01
EDGE-Lung
Gilead Sciences
Phase 2
Active not recruiting
400 enrolled